title: Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens.
abstract: BACKGROUND
  Cytoplasmic p90 autoantigen was recently cloned from a cDNA expression library using serum antibody from a cancer patient. The humoral immune response to p90 in prostate cancer and benign prostatic hyperplasia (BPH) was examined.
  
  
  METHODS
  An antigenic fragment of recombinant p90 protein and several other tumor-associated antigens (TAAs) were used in ELISA and Western blotting to detect antibodies in sera from patients with prostate cancer, BPH, and other controls.
  
  
  RESULTS
  Autoantibodies to p90 were detected in 30.8% of 133 prostate cancer patients versus 1.5% in 68 BPH patients. When a selected panel of six TAAs including p90 were used for immunoscreening, the cumulative positive reactions in prostate cancer sera reached 92.5%, significantly higher than in BPH and other control sera. Antibodies to p90 showed the highest frequency in prostate cancer (30.8%), followed by antibodies to p62 (22.6%).
  
  
  CONCLUSIONS
  A panel of six selected TAAs was shown to have high sensitivity and specificity as immunodiagnostic markers in prostate cancer.
authors.affiliation: Department of Molecular and Experimental Medicine, W.M. Keck Autoimmune Disease Center, The Scripps Research Institute, La Jolla, California, USA.
authors.forename: Fu-Dong
authors.initials: FD
authors.lastname: Shi
authors.forename: Jian-Ying
authors.initials: JY
authors.lastname: Zhang
authors.forename: Daorong
authors.initials: D
authors.lastname: Liu
authors.forename: Ann
authors.initials: A
authors.lastname: Rearden
authors.forename: Max
authors.initials: M
authors.lastname: Elliot
authors.forename: Dan
authors.initials: D
authors.lastname: Nachtsheim
authors.forename: Tracy
authors.initials: T
authors.lastname: Daniels
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Casiano
authors.forename: Mary Jo
authors.initials: MJ
authors.lastname: Heeb
authors.forename: Edward K L
authors.initials: EK
authors.lastname: Chan
authors.forename: Eng M
authors.initials: EM
authors.lastname: Tan
mesh_terms: D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood*; D001324:Autoantigens / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000032:analysis*; D015153:Blotting, Western; D016213:Cyclins / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D008297:Male; D008565:Membrane Proteins; D010446:Peptide Fragments / Q000276:immunology; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000276:immunology*; D016271:Proto-Oncogene Proteins c-myc / Q000276:immunology; D012333:RNA, Messenger; D016601:RNA-Binding Proteins / Q000276:immunology*; D011994:Recombinant Proteins; D012680:Sensitivity and Specificity; D016159:Tumor Suppressor Protein p53 / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D001323:Autoantibodies; D001324:Autoantigens; D014408:Biomarkers, Tumor; C500266:CIP2A protein, human; D016213:Cyclins; D047908:Intracellular Signaling Peptides and Proteins; C489427:MYC protein, human; D008565:Membrane Proteins; C118585:P62 protein, human; D010446:Peptide Fragments; D016271:Proto-Oncogene Proteins c-myc; D012333:RNA, Messenger; D016601:RNA-Binding Proteins; D011994:Recombinant Proteins; D016159:Tumor Suppressor Protein p53; D017430:Prostate-Specific Antigen